FDA Lashes Out

Allergan Inc, the maker of Botox, said on Friday that the U.S. Food and Drug Administration has approved its eyelash-thickening drug Latisse.
The active ingredient in Latisse is bimatroprost, the same ingredient that is in Allergan's glaucoma treatment Lumigan. Patients taking Lumigan found a side effect of the drug to be eyelash growth, prompting Allergan to study it for the new use.
Latisse is a once-daily prescription treatment that is applied to the base of the upper eyelash with a sterile, single-use-per-eye disposable applicator. Once treatment is stopped, eyelashes will gradually return to where they were prior to treatment.
Reuters report HERE